英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
Pithiest查看　Pithiest　在百度字典中的解释百度英翻中〔查看〕
Pithiest查看　Pithiest　在Google字典中的解释Google英翻中〔查看〕
Pithiest查看　Pithiest　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Metastatic Hormone-Sensitive Prostate Cancer (mHSPC . . .
    The treatment landscape of metastatic hormone-sensitive prostate cancer (mHSPC) has changed radically in recent years Androgen deprivation therapy (ADT) alone was for decades the standard of care for treating mHSPC This changed when studies showed
  • Treatment of Metastatic Hormone-Sensitive Prostate Cancer
    Treatment of metastatic prostate cancer is generally based on whether its growth can be slowed or stopped with hormone therapy Recall that testosterone (an androgen hormone) is the “fuel” that makes prostate cancer cells grow Initially, growth of recurrent or metastatic prostate cancer may stop or slow down in a low-testosterone environment
  • Rethinking Advanced Prostate Cancer: Surprising Finds From a . . .
    New research reveals that radiotherapy benefits prostate cancer patients with fewer metastases, refining treatment strategies for advanced cases
  • Emerging Paradigms in Metastatic Hormone-Sensitive Prostate . . .
    Dr Jordan Ciuro Key Points: The metastatic hormone-sensitive prostate cancer (mHSPC) treatment landscape has evolved from androgen deprivation therapy (ADT) monotherapy to doublet and triplet regimens, with clinical factors like disease volume and risk as well as metachronous or synchronous presentation guiding intensification decisions Molecular tools such as gene expression profiling
  • Combination Therapies in Locally Advanced and Metastatic . . .
    This narrative collaborative review summarises the data behind combination treatment approaches for locally advanced prostate cancer (LAPC) and mHSPC, and discusses on-going challenges and clinical considerations
  • Current landscape in first-line treatment of metastatic . . .
    Abstract Contemporary treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has evolved significantly over the past decade with the introduction of upfront combination therapies (ie, ADT plus androgen receptor pathway inhibitors (ARPIs), with or without docetaxel), previously reserved for more advanced stages of the disease
  • Optimizing Advanced Prostate Cancer Care: Balancing . . .
    The conversation explores optimal sequencing, with Dr Attard advocating for moving PARP inhibitors to first-line metastatic hormone-sensitive prostate cancer in appropriate patients to maximize response and prevent missed treatment opportunities
  • A Phase 2 Study to Evaluate the Effects of ASP5541 in . . .
    Adult men with a certain type of advanced prostate cancer can take part Their cancer has spread to other parts of the body (metastatic) The different types are: Metastatic hormone-sensitive prostate cancer (mHSPC) Prostate cancer that needs testosterone to grow Metastatic castration-resistant prostate cancer (mCRPC)
  • Darolutamide + Androgen-Deprivation Therapy Provides . . .
    Saad F, Vjaters E, Shore N, et al Efficacy and safety of darolutamide plus androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase 3 Aranote trial
  • Beyond Hormones Innovative Strategies to Combat Prostate Cancer
    News Publications Beyond Hormones Innovative Strategies to Combat Prostate Cancer CRM1 is an important linchpin that keeps the wheel of advanced prostate cancer turning A drug called Selinexor, already approved for treating other cancers, targets it





中文字典-英文字典  2005-2009